Evidence map›Paper›PMID 41780106›Full record

ReviewCurrent opinion in microbiology2026

Advances in biocontainment strategies of engineered microbes for use in humans.

Jay Fuerte-Stone, Mark Mimee

Abstract readReview
In one paragraph

Review in Current opinion in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jay Fuerte-StoneCommittee on Microbiology, University of Chicago, Chicago, IL 60637, USA.
Mark MimeeCommittee on Microbiology, University of Chicago, Chicago, IL 60637, USA; Department of Microbiology, University of Chicago, Chicago, IL 60637, USA; Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA. Electronic address: mmimee@uchicago.edu.

Funding

Molecular And Cellular Biology Training ProgramT32GM007183 · NIGMS · UNIVERSITY OF CHICAGO · PI GLICK, BENJAMIN S, RICE, PHOEBE A · 1985 to 2021
$23.9M
University of Chicago Initiative for Maximizing Student Development (IMSD) - Renewal 01R25GM109439 · NIGMS · UNIVERSITY OF CHICAGO · PI SCHWARTZ, NANCY B · 2014 to 2023
$5.7M
Genetically-engineered Bacteria Overcome Therapy ResistanceR01CA292860 · NCI · UNIVERSITY OF CHICAGO · PI Mark Mimee, RALPH R WEICHSELBAUM · 2024 to 2026
$2.9M
Microbial Engineering to Control the Structure and Function of the Gut Microbiome.R35GM147478 · NIGMS · UNIVERSITY OF CHICAGO · PI Mark Mimee · 2022 to 2026
$2.0M
NCI NIH HHS R01 CA292860NIGMS NIH HHS R25 GM109439NIGMS NIH HHS R35 GM147478NIGMS NIH HHS T32 GM007183
6 · The paper itself

Abstract

Genetically engineered microorganisms have been designed for use in many aspects of medicine. Advances in synthetic biology allow for the design of these organisms for a wide number of uses in a variety of environments. However, these advances are accompanied by the need for robust biocontainment strategies to prevent unwanted colonization and dissemination of engineered microorganisms. In this review, we discuss the current state of biocontainment strategies for use in biomedical applications. Many biocontainment strategies exist, including toxin-antitoxin systems, kill switches, auxotrophy, CRISPR-based targeted DNA degradation, nonstandard amino acids, and physical barriers. We discuss the use and caveats of these strategies both alone and in combination with each other. Additionally, we discuss the use and efficacy of these strategies in clinical trials. Finally, we discuss the need for standardized testing of containment escape. As use of these engineered microorganisms progresses, it is paramount that containment strategies advance with them to ensure safety, minimize environmental impact, and maintain a positive public view of this important work.

Indexed as

Containment of BiohazardsGenetic EngineeringMicroorganisms, Genetically-ModifiedBacteriaHumansSynthetic Biology

Identifiers

PMID41780106
PMCPMC13072655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.